More recently, chimeric antigen receptor (CAR)-T cells targeting BCMA and/or TACI and anti-BCMA mAbs show promising effects in the treatment of multiple myeloma [38, 53], and autoimmune disease [12], including an ongoing clinical trial in generalized MG (ClinicalTrials.gov Identifier: NCT04146051). Here, TNFRSF13B is linked to AL amyloidosis.